PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14558594-2	2003	The results show that thalidomide inhibits endotelial cell proliferation induced by bFGF and VEGF, more so if the cells are grown on vitronectin; moreover, treatment with thalidomide reduces the release of MMP-2 and IL-8 by endothelial cells, suggesting a further pathway for the antiangiogenic activity of drug.	Thalidomide	22-33	vitronectin	Homo sapiens	133-144	
14558594-2	2003	The results show that thalidomide inhibits endotelial cell proliferation induced by bFGF and VEGF, more so if the cells are grown on vitronectin; moreover, treatment with thalidomide reduces the release of MMP-2 and IL-8 by endothelial cells, suggesting a further pathway for the antiangiogenic activity of drug.	Thalidomide	171-182	vitronectin	Homo sapiens	133-144	
10357564-11	1999	Comparison of cDNA expression arrays hybridized with thalidomide-treated LNCaP cDNA probes suggests that thalidomide may up- or downregulate expression of angiogenesis-related genes, i.e., vitronectin, but these differential effects require further verification.	Thalidomide	105-116	vitronectin	Homo sapiens	189-200	
10357564-13	1999	Furthermore, preliminary data from cDNA nucleic acid arrays of thalidomide-treated LNCaP cells suggest that thalidomide upregulates a potential angiogenic modulatory protein, the vitronectin precursor, which may eventually link thalidomide"s antiangiogenic activity with modulation of angiogenic vascular integrin pathways.	Thalidomide	63-74	vitronectin	Homo sapiens	179-190	
10357564-13	1999	Furthermore, preliminary data from cDNA nucleic acid arrays of thalidomide-treated LNCaP cells suggest that thalidomide upregulates a potential angiogenic modulatory protein, the vitronectin precursor, which may eventually link thalidomide"s antiangiogenic activity with modulation of angiogenic vascular integrin pathways.	Thalidomide	108-119	vitronectin	Homo sapiens	179-190	
10357564-13	1999	Furthermore, preliminary data from cDNA nucleic acid arrays of thalidomide-treated LNCaP cells suggest that thalidomide upregulates a potential angiogenic modulatory protein, the vitronectin precursor, which may eventually link thalidomide"s antiangiogenic activity with modulation of angiogenic vascular integrin pathways.	Thalidomide	108-119	vitronectin	Homo sapiens	179-190